We are facing an explosion of scientific knowledge that we are more able to deal with, because this sort of human rationality. "Christophe Thurieau, Vice-President of the translational research in Ipsen, great expectations of the biosimulation platform launched by five industrial of the life sciences: Ipsen, Pierre Fabre, Sanofi Aventis, Servier and Bayer Cropsciences.
This platform should be able to simulate the action of drugs on human cells and predict certain interactions that occur in the body. This project, expected to last five years, enjoys a total funding of EUR 118.2 million, including aid Oséo EUR 46.3 million. "This will allow to establish a digital model that will be used at a pre-competitive stage", explains Emmanuel Canet, President of R & D in Servier.
In fact, this program entitled "biointelligence" pursues three main objectives: facilitate relationships between partners engaged on a common project, pool generic knowledge on the functioning of living and achieve clinical data from the medical follow-up of treated patients. If all goes well, this program should also give a blow of accelerator in the development of new treatments more quickly eliminating molecules without therapeutic interest.
This attempt of simulation of the living "in silico" is one of the major challenges of modern biology. Many laboratories dream for a long time of a powerful and reliable software tool to predict complex phenomena such as the toxicity of a new molecule or the exchange of information within the cell cytoplasm. It is Dassault Systèmes responsible to build this system, built on the computer concept of the "data mining". "The worlds of computing and biology meet for the first time", summarizes Christophe Thurieau.
Virtual Lab
This marriage could out new concepts, a new way to develop drugs, or even a support improved patient. This very ambitious programme should also restore morale to a sector innovation machine is down for several years.
Each industrial will develop this program according to its own priorities and its therapeutic areas. Sanofi Aventis is rather interested in modelling of the clinical trials, Pierre Fabre and Ipsen aim the understanding of the migration of cells "hitchhiking" responsible for the méta-stases. Servier, this gigantic biological database should also facilitate collaborations with the world of academic research by creating "a workspace for better understanding". This secure and interoperable platform will give participants the opportunity to fuel this virtual lab. "Pharmaceutical research is now very fragmented sites sometimes far away." "We aim primarily Oncology, because it is a discipline where translational medicine which takes place near the sick plays a very important role," said Emmanuel Canet.
The cancer is in the heart of this project, described as "visionary" by its proponents. This discipline has an explosion of fundamental knowledge and clinical data (more than 800 cancer are under development in the world), and this knowledge has become virtually impossible to manage and interpret. Signage internal cell (the transmission of information to the kernel), travel of tumor cells, the production and action of antibodies are very poorly known phenomena involving tens of thousands of parameters in cascade. Everyone relies on numerical computation to bring some light into this apparent chaos. The first results are expected in a year or two.
Thus the Group makes no chip but sells design iBut the situation remains highly variable geographical zone to anotherWay that go on holiday by car is not trivial It is reliable said at the Elysee Palace5 billion euros next year and companies 2Quiksilver has big ambitions for his new protégéAnd or the civil part Vivendi it was found to be responsibleAnd the is true for negotiating platforms5 of July 1 it will increase by 600 millionThey are interested in more readily to the execution of the contract i
